Literature DB >> 26373571

The role of reproductive hormones in epithelial ovarian carcinogenesis.

Helen Gharwan1, Kristen P Bunch2, Christina M Annunziata3.   

Abstract

Epithelial ovarian cancer comprises ∼85% of all ovarian cancer cases. Despite acceptance regarding the influence of reproductive hormones on ovarian cancer risk and considerable advances in the understanding of epithelial ovarian carcinogenesis on a molecular level, complete understanding of the biologic processes underlying malignant transformation of ovarian surface epithelium is lacking. Various hypotheses have been proposed over the past several decades to explain the etiology of the disease. The role of reproductive hormones in epithelial ovarian carcinogenesis remains a key topic of research. Primary questions in the field of ovarian cancer biology center on its developmental cell of origin, the positive and negative effects of each class of hormones on ovarian cancer initiation and progression, and the role of the immune system in the ovarian cancer microenvironment. The development of the female reproductive tract is dictated by the hormonal milieu during embryogenesis. Intensive research efforts have revealed that ovarian cancer is a heterogenous disease that may develop from multiple extra-ovarian tissues, including both Müllerian (fallopian tubes, endometrium) and non-Müllerian structures (gastrointestinal tissue), contributing to its heterogeneity and distinct histologic subtypes. The mechanism underlying ovarian localization, however, remains unclear. Here, we discuss the role of reproductive hormones in influencing the immune system and tipping the balance against or in favor of developing ovarian cancer. We comment on animal models that are critical for experimentally validating existing hypotheses in key areas of endocrine research and useful for preclinical drug development. Finally, we address emerging therapeutic trends directed against ovarian cancer.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  endocrine; hormone action; immune; ovarian cancer; reproductive

Mesh:

Substances:

Year:  2015        PMID: 26373571     DOI: 10.1530/ERC-14-0550

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  14 in total

1.  Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer.

Authors:  Qianghua Hu; Takeshi Hisamatsu; Monika Haemmerle; Min Soon Cho; Sunila Pradeep; Rajesha Rupaimoole; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Stephen T C Wong; Anil K Sood; Vahid Afshar-Kharghan
Journal:  Clin Cancer Res       Date:  2017-06-13       Impact factor: 12.531

2.  What's beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.

Authors:  Emanuele Perrone; Riccardo Tudisco; Pia Clara Pafundi; Davide Guido; Alessandra Ciucci; Enrica Martinelli; Gian Franco Zannoni; Alessia Piermattei; Saveria Spadola; Giulia Ferrante; Claudia Marchetti; Giovanni Scambia; Anna Fagotti; Daniela Gallo
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

Review 3.  Drug repurposing-an emerging strategy in cancer therapeutics.

Authors:  Khadija Shahab Turabi; Ankita Deshmukh; Sayan Paul; Dayanand Swami; Shafina Siddiqui; Urwashi Kumar; Shreelekha Naikar; Shine Devarajan; Soumya Basu; Manash K Paul; Jyotirmoi Aich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-06-13       Impact factor: 3.195

4.  Decreased risk of ovarian cancer associated with rs9898876 sex hormone-binding globulin gene variant.

Authors:  Sabrina Zidi; Mouna Stayoussef; Feryel K Sontini; Amel Mezlini; Besma Yacoubi-Loueslati; Wassim Y Almawi
Journal:  Mol Biol Rep       Date:  2022-03-11       Impact factor: 2.742

5.  Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.

Authors:  Katarzyna M Terlikowska; Bozena Dobrzycka; Anna M Witkowska; Beata Mackowiak-Matejczyk; Tomasz Kamil Sledziewski; Maciej Kinalski; Slawomir J Terlikowski
Journal:  J Ovarian Res       Date:  2016-07-19       Impact factor: 4.234

6.  A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.

Authors:  Matthew R Russell; Ciaren Graham; Alfonsina D'Amato; Aleksandra Gentry-Maharaj; Andy Ryan; Jatinderpal K Kalsi; Carol Ainley; Anthony D Whetton; Usha Menon; Ian Jacobs; Robert L J Graham
Journal:  Br J Cancer       Date:  2017-06-29       Impact factor: 7.640

7.  A novel potential role of pituitary gonadotropins in the pathogenesis of human colorectal cancer.

Authors:  Wojciech Marlicz; Agata Poniewierska-Baran; Sylwia Rzeszotek; Rafał Bartoszewski; Karolina Skonieczna-Żydecka; Teresa Starzyńska; Mariusz Z Ratajczak
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

8.  Senescent peritoneal mesothelium creates a niche for ovarian cancer metastases.

Authors:  Justyna Mikuła-Pietrasik; Paweł Uruski; Patrycja Sosińska; Konstantin Maksin; Hanna Piotrowska-Kempisty; Małgorzata Kucińska; Marek Murias; Sebastian Szubert; Aldona Woźniak; Dariusz Szpurek; Stefan Sajdak; Katarzyna Piwocka; Andrzej Tykarski; Krzysztof Książek
Journal:  Cell Death Dis       Date:  2016-12-29       Impact factor: 8.469

9.  Association of four genetic polymorphisms in the vascular endothelial growth factor-A gene and development of ovarian cancer: a meta-analysis.

Authors:  Chao-Huan Xu; Zhong-Hui He; Hong Xu
Journal:  Oncotarget       Date:  2017-08-21

10.  Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium.

Authors:  Preety Bajwa; Prathima B Nagendra; Sarah Nielsen; Subhransu S Sahoo; Amanda Bielanowicz; Janine M Lombard; J Erby Wilkinson; Richard A Miller; Pradeep S Tanwar
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.